Tags

Type your tag names separated by a space and hit enter

Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Postgrad Med. 2012 May; 124(3):16-27.PM

Abstract

Overactive bladder (OAB) is a common syndrome that affects both men and women. First-line therapies for the management of OAB symptoms consist of antimuscarinic agents and behavioral therapy, ideally used in combination. Although effective in improving OAB symptoms, the use of antimuscarinic therapy may be limited by side effects, contraindications, and insufficient response. Current second-line therapies include sacral nerve stimulation and percutaneous tibial nerve stimulation. These therapies have been shown to be useful in treating OAB symptoms, but are more invasive and time-consuming than medical therapy. Onabotulinum toxin A is currently under investigation for idiopathic OAB, as well as the β-3-adreno-renoreceptor agonists mirabegron and solabegron. The role of these agents, with different mechanisms of action, in the pharmacologic management of OAB remains to be determined, although they appear to be promising alternatives and possible adjuncts to current pharmacologic and behavioral therapy. This article discusses second-line and current and future therapies for the management of OAB symptoms.

Authors+Show Affiliations

Division of Urology, Warren Alpert School of Medicine/Brown University, Providence, RI 02905, USA. pamelaellsworth@aol.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22691895

Citation

Ellsworth, Pamela. "Treatment of Overactive Bladder Symptoms Beyond Antimuscarinics: Current and Future Therapies." Postgraduate Medicine, vol. 124, no. 3, 2012, pp. 16-27.
Ellsworth P. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. Postgrad Med. 2012;124(3):16-27.
Ellsworth, P. (2012). Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. Postgraduate Medicine, 124(3), 16-27. https://doi.org/10.3810/pgm.2012.05.2544
Ellsworth P. Treatment of Overactive Bladder Symptoms Beyond Antimuscarinics: Current and Future Therapies. Postgrad Med. 2012;124(3):16-27. PubMed PMID: 22691895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. A1 - Ellsworth,Pamela, PY - 2012/6/14/entrez PY - 2012/6/14/pubmed PY - 2012/10/25/medline SP - 16 EP - 27 JF - Postgraduate medicine JO - Postgrad Med VL - 124 IS - 3 N2 - Overactive bladder (OAB) is a common syndrome that affects both men and women. First-line therapies for the management of OAB symptoms consist of antimuscarinic agents and behavioral therapy, ideally used in combination. Although effective in improving OAB symptoms, the use of antimuscarinic therapy may be limited by side effects, contraindications, and insufficient response. Current second-line therapies include sacral nerve stimulation and percutaneous tibial nerve stimulation. These therapies have been shown to be useful in treating OAB symptoms, but are more invasive and time-consuming than medical therapy. Onabotulinum toxin A is currently under investigation for idiopathic OAB, as well as the β-3-adreno-renoreceptor agonists mirabegron and solabegron. The role of these agents, with different mechanisms of action, in the pharmacologic management of OAB remains to be determined, although they appear to be promising alternatives and possible adjuncts to current pharmacologic and behavioral therapy. This article discusses second-line and current and future therapies for the management of OAB symptoms. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/22691895/Treatment_of_overactive_bladder_symptoms_beyond_antimuscarinics:_current_and_future_therapies_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2012.05.2544 DB - PRIME DP - Unbound Medicine ER -